Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blind Placebo-controlled Study to Assess the Efficacy and Safety of Oral Tafenoquine Versus Placebo in Patients With Mild to Moderate COVID-19 Disease

NCT04533347 is registered in ClinicalTrials.gov with 60 Degrees Pharmaceuticals LLC as lead sponsor.

NCT NCT04533347
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04533347 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blind Placebo-controlled Study to Assess the Efficacy and Safety of Oral Tafenoquine Versus Placebo in Patients With Mild to Moderate COVID-19 Disease
Lead sponsor
60 Degrees Pharmaceuticals LLC
Phase
Phase 2
Overall status
Completed
Start date
February 19, 2021
Completion date
June 30, 2022
Enrollment
86 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

covid 19 disease